RxDoctor Payments Data
★ My doctorsLook up a doctor →

Louis Guzzi, MD

Critical Care Medicine · Orlando, FLNPI 1215923180

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $406,873 of the $635,061 with a category attached, or 64.1%. 30 manufacturers reported payments, led by AstraZeneca at 34.9% of the total. Reporting peaked in 2019 at $153,342 and has fallen 58.7% since, to $63,277 in 2025. Among critical care medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$635,061in general payments, 2019–2025

Across 856 payments — averaging $741.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$222K
  • La Jolla Pharmaceutical Company$101K
  • Edwards Lifesciences$97K
  • Biomerieux Inc$95K
  • Acelrx Pharmaceuticals, Inc.$31K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$31K
  • plus $59K from 24 others
$4,875in research payments, 2019–2025

Across 2 payments — averaging $2437.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biomerieux Inc$5K

What the payments were for

  • Consulting fees$144,45923%
  • Speaking & faculty fees$406,87364%
  • Grants$6800%
  • Travel & lodging$59,6739%
  • Food & beverage$23,3494%
  • Education$270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)305$221,846
La Jolla Pharmaceutical Company96$100,724
Edwards Lifesciences140$96,719
Biomerieux Inc87$95,089
Acelrx Pharmaceuticals, Inc.41$31,122
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC58$30,803
BD16$19,312
Baudax Bio Inc.17$14,093
Fresenius Kabi USA, LLC30$11,760
BTG International Inc.2$6,703
Gilead1$2,200
Abiomed19$901
Portola Pharmaceuticals, LLC1$900
C. R. Bard, Inc. & Subsidiaries1$594
Smiths Medical ASD, Inc.1$518
Merck8$258
Nxstage Medical, Inc.3$241
Boehringer Ingelheim2$221
Melinta Therapeutics, LLC11$177
Medtronic(2 entities)3$172
Genentech USA, Inc.1$129
Mallinckrodt Hospital Products Inc.1$108
Ferring Pharmaceuticals Inc.1$101
Novo Nordisk1$99
Johnson & Johnson1$98
Getinge USA Sales, LLC4$78
Nuwellis, Inc.2$39
AbbVie1$22
Pentax Of America, Inc.1$18
Boston Scientific1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$635,061 in reported general payments places this provider in the 95th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida →

Medicare billing

Part B allowed, 2024
$82,953
Medicare patients
579
Services billed
738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other critical care medicine in Orlando

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →